Background: Alzheimer's disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). However, polymorphisms also exist within these genes. Methods: In order to distinguish polymorphisms from pathogenic mutations, the DIAN Expanded Registry has implemented an algorithm for determining ADAD pathogenicity using available information from multiple domains, including genetic, bioinformatic, clinical, imaging, and biofluid measures and in vitro analyses. Results: We propose that PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and APP T719N are likely pathogenic mutations, whereas PSEN1 c.379-382delXXXXinsG and PSEN2 L238F have uncertain pathogenicity. Conclusions: In defining a subset of these variants as pathogenic, individuals from these families can now be enrolled in observational and clinical trials. This study outlines a critical approach for translating genetic data into meaningful clinical outcomes.

Original languageEnglish
Article number67
JournalAlzheimer's Research and Therapy
Issue number1
StatePublished - Jul 18 2018


  • APP
  • Autosomal dominant Alzheimer's disease
  • Cell-based assays
  • PSEN1
  • PSEN2
  • Pathogenicity algorithm


Dive into the research topics of 'Discovery and validation of autosomal dominant Alzheimer's disease mutations'. Together they form a unique fingerprint.

Cite this